This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

The entrance to the Rolls Building, which houses the Business and Property Courts of England and Wales. A court in the UK has said that GSK should pay AstraZeneca a higher royalty rate on sales of ...

Night - Clear. Winds from NW to WNW. The overnight low will be 65 °F (18.3 °C). Partly cloudy with a high of 79 °F (26.1 °C) and a 51% chance of precipitation. Winds from WNW to W at 4 to 6 ...

GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare Conference, the European healthcare giant noted there ...

The FDA has granted breakthrough therapy designation to GSK5764227 (GSK’227; HS-20093), a B7-H3-targeted antibody-drug conjugate (ADC), for the treatment of adult patients with relapsed or refractory ...

GSK PLC GSK shares shed 2.82% to £12.94 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100 Index UKX falling 0.28% to 8,201.54. Supported by ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Subscribe to The Economic Times Prime and read the ET ePaper online.

Is the fren­zy of JPM deal­mak­ing fi­nal­ly un­der­way? GSK an­nounced Mon­day morn­ing that it will ac­quire the pri­vate­ly-held biotech IDRx for $1 bil­lion up­front, bring­ing … ...

Investing.com -- GSK Plc's CEO Emma Walmsley has expressed intentions to engage in more business deals, as the British pharmaceutical company intensifies its focus on cancer treatments.

The British pharma giant plans to shell out $1 billion upfront to buy the drug developer working on a lead treatment for gastrointestinal stromal tumors. As the first morning of the J.P. Morgan ...